Picard Medical/ SynCardia to Present at European Mechanical Circulatory Support Summit and International Course on Mechanical Circulatory Support and New Technologies in Heart Failure

Rhea-AI Summary

Picard Medical (NYSE American: PMI) announced that Dr. Andre Simon, Vice President of Clinical Affairs, will present data on the fully implantable Emperor Total Artificial Heart (TAH) at the 19th EUMS & 11th International Course on Mechanical Circulatory Support, Feb 15–18, 2026 in Barcelona.

The presentation, titled "The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart," is scheduled for February 16, 2026 at 17:15 CET.

News Market Reaction

-2.89%

3 alerts

-2.89% News Effect

-$4M Valuation Impact

$128M Market Cap

0.0x Rel. Volume

On the day this news was published, PMI declined 2.89%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $128M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 19th EUMS summit Course edition: 11th International Course Conference dates: Feb 15–18, 2026 +2 more

5 metrics

Conference edition 19th EUMS summit European Mechanical Circulatory Support Summit

Course edition 11th International Course Mechanical Circulatory Support and New Technologies in HF

Conference dates Feb 15–18, 2026 Barcelona congress dates

Presentation date Feb 16, 2026 Emperor Total Artificial Heart session date

Presentation time 17:15–18:15 CET Session on advances in short-term MCS and HF

Market Reality Check

Price: $1.61 Vol: Volume 56,011 is at 0.36x...

low vol

$1.61 Last Close

Volume Volume 56,011 is at 0.36x the 20-day average of 157,426, indicating muted trading interest pre-announcement. low

Technical Shares at $1.73 are trading below the 200-day MA of $2.77 and remain 87.35% under the 52-week high.

Peers on Argus

PMI fell 7.98% while close peers were mixed: CTKB at -0.78%, KIDS at +0.42%, and...

PMI fell 7.98% while close peers were mixed: CTKB at -0.78%, KIDS at +0.42%, and several flat. With no peers in the momentum scanner, the move appears stock-specific rather than a sector rotation.

Common Catalyst One peer (LAB) had an earnings-date announcement, but broader device peers did not show coordinated moves tied to PMI’s conference presentation.

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Webinar announcement	Positive	+0.0%	Announced DeviceTalks webinar on Emperor fully implantable total artificial heart.
Jan 13	Media/podcast outreach	Positive	+4.8%	Cruxx to MedTech podcast series highlighting SynCardia TAH and Emperor device.
Jan 12	Development collaboration	Positive	-1.2%	Collaboration with Hydrix to advance Emperor next‑generation total artificial heart.
Jan 07	Conference participation	Positive	+10.4%	Participation in multiple JPM week conferences and investor meetings.
Jan 06	Product rollout	Positive	+3.6%	Rollout of FDA-cleared CPC1 Connector Covers into SynCardia TAH design.

Pattern Detected

Recent corporate and visibility updates have more often coincided with flat-to-positive price reactions, with only one negative reaction in the last five events.

Recent Company History

Over the past several weeks, Picard Medical has issued a series of visibility and product-focused updates. On Jan 6, 2026, it announced rollout of an FDA-cleared accessory, with a +3.59% reaction. A conference participation update on Jan 7 saw a +10.4% move, while a development collaboration on Jan 12 coincided with a modest -1.19% decline. A MedTech podcast feature on Jan 13 led to a +4.82% gain, and a Jan 29 webinar notice saw a flat reaction. Today’s conference-presentation news fits this ongoing outreach pattern.

Market Pulse Summary

This announcement highlights another scientific and clinical visibility milestone for Picard Medical...

Analysis

This announcement highlights another scientific and clinical visibility milestone for Picard Medical’s Emperor Total Artificial Heart, with data to be presented at a major European congress on Feb 16, 2026. It continues a series of outreach efforts including webinars, podcasts, and conference appearances focused on the SynCardia platform. Investors may watch for the quality and reception of in vitro and in vivo data, future regulatory updates, and how these activities translate into commercial and balance-sheet developments.

Key Terms

total artificial heart, mechanical circulatory support, advanced heart failure, in vitro, +2 more

6 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

mechanical circulatory support medical

"European Mechanical Circulatory Support Summit & 11th International Course on Mechanical"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

advanced heart failure medical

"New Technologies in Advanced Heart Failure (HF) congress, being held"

Advanced heart failure is a severe, chronic condition in which the heart can no longer pump enough blood to meet the body's needs despite standard treatments, causing frequent symptoms, hospital stays, and the need for specialized therapies. For investors, it signals a clear market for high-cost interventions—drugs, medical devices, hospitals and transplant or mechanical support technologies—so clinical results, approvals, and reimbursement decisions can materially affect revenue, costs and company valuations; think of it as a failing engine that requires costly, often long-term repairs or replacement.

in vitro medical

"The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

in vivo medical

"The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

electromechanical technical

"Evaluation of SynCardia’s Electromechanical Total Artificial Heart"

A device, system or process that combines electrical energy and mechanical movement to perform work or control motion, like an electric motor turning gears or a sensor triggering a valve. Investors care because electromechanical products link hardware, manufacturing complexity and maintenance costs to revenue potential; reliability, supply chains and regulation can affect earnings and valuation in companies that design, make or use these components.

AI-generated analysis. Not financial advice.

TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th International Course on Mechanical Circulatory Support (MCS) and New Technologies in Advanced Heart Failure (HF) congress, being held February 15^th - 18^th, 2026 in Barcelona, Spain.

Details of the presentation are below:

Date: Monday, February 16, 2026
Time: 17:15 – 18:15 Central European Time
Session: Latest Advances in Short-Term MCS and Advanced Heart Failure
Presentation Title: The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart

About the European Mechanical Circulatory Support Summit

The European Mechanical Circulatory Support Summit (EUMS) (www.congresseums.com) is a leading international forum dedicated to advancing mechanical circulatory support and emerging technologies in the treatment of advanced heart failure. EUMS has joined with Bellvitge University Hospital for the 19th EUMS & 11th International Course on MCS New Technologies in HF to bring together leading clinicians, researchers and industry experts from around the world to share the latest clinical experience technological innovation and best practices in patient care. The congress features high level scientific sessions expert panels and interactive casebased discussions designed to foster collaboration and accelerate progress in this rapidly evolving field.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When will Picard Medical (PMI) present Emperor TAH data at the EUMS/MCS congress in 2026?

Picard Medical will present on February 16, 2026 at 17:15 CET. According to the company, Dr. Andre Simon will present first in vitro and in vivo evaluation data for the Emperor electromechanical Total Artificial Heart during the session on latest advances.

What is the presentation title for SynCardia’s Emperor Total Artificial Heart at the Feb 2026 conference?

The presentation is titled "The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart". According to the company, it will appear in the session on short-term MCS and advanced heart failure on February 16, 2026.

Who from Picard Medical (PMI) will present Emperor TAH findings at the Barcelona congress?

Dr. Andre Simon, Vice President of Clinical Affairs, will present the data. According to the company, he will discuss the fully implantable Emperor TAH during the 19th EUMS & 11th International Course session on February 16, 2026.

What topics will Picard Medical (PMI) cover in the Emperor TAH presentation at EUMS 2026?

The talk covers first in vitro and in vivo evaluations of the Emperor electromechanical Total Artificial Heart. According to the company, the presentation addresses experimental and preclinical performance within the session on MCS and advanced heart failure.

Where and when is the 19th EUMS & 11th International Course on MCS where PMI will present?

The congress takes place in Barcelona, Spain, February 15–18, 2026. According to the company, Picard Medical’s presentation is scheduled for February 16, 2026 at 17:15 Central European Time during the MCS and new technologies session.